Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2022 06:00 ET | Source: ALX Oncology

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block...
January 04, 2022 07:00 ET | Source: ALX Oncology

ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the...
December 12, 2021 09:00 ET | Source: ALX Oncology

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS -- Objective responses...
November 11, 2021 16:05 ET | Source: ALX Oncology

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block...
November 09, 2021 07:00 ET | Source: ALX Oncology

ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors

-- ORR of 72.2%, mDOR of 14.8 months, 12-month OS rate of 79%, and mOS of 17.1 months in Patients with >2L HER2 Positive Gastric/Gastroesophageal Junction Cancer -- -- 12-month OS rate of 87.5% and...
November 04, 2021 09:00 ET | Source: ALX Oncology

ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the...
November 02, 2021 09:00 ET | Source: ALX Oncology

ALX Oncology Announces Upcoming Virtual Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block...
October 21, 2021 07:00 ET | Source: ALX Oncology

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
October 07, 2021 07:00 ET | Source: ALX Oncology

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugatesExpands ALX...
October 01, 2021 08:00 ET | Source: ALX Oncology

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block...